Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.

PMID:
29988124
2.

Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.

Lin GL, Nagaraja S, Filbin MG, Suvà ML, Vogel H, Monje M.

Acta Neuropathol Commun. 2018 Jun 28;6(1):51. doi: 10.1186/s40478-018-0553-x.

3.

Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.

Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT.

NPJ Precis Oncol. 2017 Sep 18;1(1):33. doi: 10.1038/s41698-017-0035-9. eCollection 2017.

4.

A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.

Griveau A, Seano G, Shelton SJ, Kupp R, Jahangiri A, Obernier K, Krishnan S, Lindberg OR, Yuen TJ, Tien AC, Sabo JK, Wang N, Chen I, Kloepper J, Larrouquere L, Ghosh M, Tirosh I, Huillard E, Alvarez-Buylla A, Oldham MC, Persson AI, Weiss WA, Batchelor TT, Stemmer-Rachamimov A, Suvà ML, Phillips JJ, Aghi MK, Mehta S, Jain RK, Rowitch DH.

Cancer Cell. 2018 May 14;33(5):874-889.e7. doi: 10.1016/j.ccell.2018.03.020. Epub 2018 Apr 19.

PMID:
29681511
5.

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popović M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML.

Science. 2018 Apr 20;360(6386):331-335. doi: 10.1126/science.aao4750.

PMID:
29674595
6.

Toward methylation-based classification of central nervous system tumors.

Hegi ME, Kleihues P, Wen PY, Suvà ML.

Neuro Oncol. 2018 Apr 9;20(5):579-581. doi: 10.1093/neuonc/noy023. No abstract available.

PMID:
29584921
7.

Dissecting human gliomas by single-cell RNA sequencing.

Tirosh I, Suvà ML.

Neuro Oncol. 2018 Jan 10;20(1):37-43. doi: 10.1093/neuonc/nox126.

PMID:
29016805
8.

Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single-cell resolution using RNA sequencing.

Tang Q, Iyer S, Lobbardi R, Moore JC, Chen H, Lareau C, Hebert C, Shaw ML, Neftel C, Suva ML, Ceol CJ, Bernards A, Aryee M, Pinello L, Drummond IA, Langenau DM.

J Exp Med. 2017 Oct 2;214(10):2875-2887. doi: 10.1084/jem.20170976. Epub 2017 Sep 6.

9.

Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.

Yu D, Khan OF, Suvà ML, Dong B, Panek WK, Xiao T, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Zhang HF, Sun C, Langer R, Anderson DG, Lesniak MS.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6147-E6156. doi: 10.1073/pnas.1701911114. Epub 2017 Jul 10.

10.

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante LE, Shaw ML, Rodman C, Gillespie SM, Dionne D, Luo CC, Ravichandran H, Mylvaganam R, Mount C, Onozato ML, Nahed BV, Wakimoto H, Curry WT, Iafrate AJ, Rivera MN, Frosch MP, Golub TR, Brastianos PK, Getz G, Patel AP, Monje M, Cahill DP, Rozenblatt-Rosen O, Louis DN, Bernstein BE, Regev A, Suvà ML.

Science. 2017 Mar 31;355(6332). pii: eaai8478. doi: 10.1126/science.aai8478.

11.

Purine synthesis promotes maintenance of brain tumor initiating cells in glioma.

Wang X, Yang K, Xie Q, Wu Q, Mack SC, Shi Y, Kim LJY, Prager BC, Flavahan WA, Liu X, Singer M, Hubert CG, Miller TE, Zhou W, Huang Z, Fang X, Regev A, Suvà ML, Hwang TH, Locasale JW, Bao S, Rich JN.

Nat Neurosci. 2017 May;20(5):661-673. doi: 10.1038/nn.4537. Epub 2017 Mar 27.

12.

Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.

Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, Hebert CH, Carey CD, Rodig SJ, Shareef SJ, Najm FJ, van Galen P, Wakimoto H, Cahill DP, Rich JN, Aster JC, Suvà ML, Patel AP, Bernstein BE.

Cell Stem Cell. 2017 Feb 2;20(2):233-246.e7. doi: 10.1016/j.stem.2016.11.003. Epub 2016 Dec 15.

13.

IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer.

Degrauwe N, Suvà ML, Janiszewska M, Riggi N, Stamenkovic I.

Genes Dev. 2016 Nov 15;30(22):2459-2474. Review.

14.

Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.

Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman C, Mount C, Filbin MG, Neftel C, Desai N, Nyman J, Izar B, Luo CC, Francis JM, Patel AA, Onozato ML, Riggi N, Livak KJ, Gennert D, Satija R, Nahed BV, Curry WT, Martuza RL, Mylvaganam R, Iafrate AJ, Frosch MP, Golub TR, Rivera MN, Getz G, Rozenblatt-Rosen O, Cahill DP, Monje M, Bernstein BE, Louis DN, Regev A, Suvà ML.

Nature. 2016 Nov 10;539(7628):309-313. doi: 10.1038/nature20123. Epub 2016 Nov 2.

15.

The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing.

Degrauwe N, Schlumpf TB, Janiszewska M, Martin P, Cauderay A, Provero P, Riggi N, Suvà ML, Paro R, Stamenkovic I.

Cell Rep. 2016 May 24;15(8):1634-47. doi: 10.1016/j.celrep.2016.04.086. Epub 2016 May 12.

16.

Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time.

Filbin MG, Suvà ML.

Annu Rev Pathol. 2016 May 23;11:497-521. doi: 10.1146/annurev-pathol-012615-044208. Epub 2016 Mar 2. Review.

PMID:
26980161
17.

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suvà ML, Bernstein BE.

Nature. 2016 Jan 7;529(7584):110-4. doi: 10.1038/nature16490. Epub 2015 Dec 23.

18.

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber DA, Boussin FD, Zou L.

Science. 2015 Jan 16;347(6219):273-7. doi: 10.1126/science.1257216.

19.

EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.

Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O, Cook EB, Formey A, Patel A, Gymrek M, Thapar V, Deshpande V, Ting DT, Hornicek FJ, Nielsen GP, Stamenkovic I, Aryee MJ, Bernstein BE, Rivera MN.

Cancer Cell. 2014 Nov 10;26(5):668-681. doi: 10.1016/j.ccell.2014.10.004. Epub 2014 Oct 30.

20.

Genetics and epigenetics of gliomas.

Suvà ML.

Swiss Med Wkly. 2014 Oct 30;144:w14018. doi: 10.4414/smw.2014.14018. eCollection 2014. Review.

21.

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE.

Science. 2014 Jun 20;344(6190):1396-401. doi: 10.1126/science.1254257. Epub 2014 Jun 12.

22.

Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE.

Cell. 2014 Apr 24;157(3):580-94. doi: 10.1016/j.cell.2014.02.030. Epub 2014 Apr 10.

23.

Next-generation molecular genetics of brain tumours.

Suvà ML, Louis DN.

Curr Opin Neurol. 2013 Dec;26(6):681-7. doi: 10.1097/WCO.0000000000000027. Review.

PMID:
24184972
24.

An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.

Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE.

Cell Rep. 2013 May 30;3(5):1567-79. doi: 10.1016/j.celrep.2013.04.021. Epub 2013 May 23.

25.

Epigenetic reprogramming in cancer.

Suvà ML, Riggi N, Bernstein BE.

Science. 2013 Mar 29;339(6127):1567-70. doi: 10.1126/science.1230184. Review.

26.

Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells.

Janiszewska M, Suvà ML, Riggi N, Houtkooper RH, Auwerx J, Clément-Schatlo V, Radovanovic I, Rheinbay E, Provero P, Stamenkovic I.

Genes Dev. 2012 Sep 1;26(17):1926-44. doi: 10.1101/gad.188292.112. Epub 2012 Aug 16.

27.

A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma.

De Vito C, Riggi N, Cornaz S, Suvà ML, Baumer K, Provero P, Stamenkovic I.

Cancer Cell. 2012 Jun 12;21(6):807-21. doi: 10.1016/j.ccr.2012.04.023.

28.

A tell-tail sign of chromatin: histone mutations drive pediatric glioblastoma.

Rheinbay E, Louis DN, Bernstein BE, Suvà ML.

Cancer Cell. 2012 Mar 20;21(3):329-31. doi: 10.1016/j.ccr.2012.03.001.

29.

Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.

De Vito C, Riggi N, Suvà ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, Stamenkovic I.

PLoS One. 2011;6(8):e23592. doi: 10.1371/journal.pone.0023592. Epub 2011 Aug 10.

30.

The cancer stem cell paradigm in Ewing's sarcoma: what can we learn about these rare cells from a rare tumor?

Riggi N, Suvà ML, Stamenkovic I.

Expert Rev Anticancer Ther. 2011 Feb;11(2):143-5. doi: 10.1586/era.10.235. No abstract available.

PMID:
21342030
31.

EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.

Riggi N, Suvà ML, De Vito C, Provero P, Stehle JC, Baumer K, Cironi L, Janiszewska M, Petricevic T, Suvà D, Tercier S, Joseph JM, Guillou L, Stamenkovic I.

Genes Dev. 2010 May;24(9):916-32. doi: 10.1101/gad.1899710. Epub 2010 Apr 9.

32.

Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.

Cironi L, Provero P, Riggi N, Janiszewska M, Suva D, Suva ML, Kindler V, Stamenkovic I.

PLoS One. 2009 Nov 19;4(11):e7904. doi: 10.1371/journal.pone.0007904.

33.

EZH2 is essential for glioblastoma cancer stem cell maintenance.

Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clément V, Stamenkovic I.

Cancer Res. 2009 Dec 15;69(24):9211-8. doi: 10.1158/0008-5472.CAN-09-1622.

34.

Ewing's sarcoma origin: from duel to duality.

Riggi N, Suva ML, Stamenkovic I.

Expert Rev Anticancer Ther. 2009 Aug;9(8):1025-30. doi: 10.1586/era.09.81. No abstract available.

PMID:
19671021
35.

Malarial hemozoin is a Nalp3 inflammasome activating danger signal.

Dostert C, Guarda G, Romero JF, Menu P, Gross O, Tardivel A, Suva ML, Stehle JC, Kopf M, Stamenkovic I, Corradin G, Tschopp J.

PLoS One. 2009 Aug 4;4(8):e6510. doi: 10.1371/journal.pone.0006510.

36.

Identification of cancer stem cells in Ewing's sarcoma.

Suvà ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suvà D, Clément V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I.

Cancer Res. 2009 Mar 1;69(5):1776-81. doi: 10.1158/0008-5472.CAN-08-2242. Epub 2009 Feb 10.

37.

IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.

Cironi L, Riggi N, Provero P, Wolf N, Suvà ML, Suvà D, Kindler V, Stamenkovic I.

PLoS One. 2008 Jul 9;3(7):e2634. doi: 10.1371/journal.pone.0002634.

38.

EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.

Riggi N, Suvà ML, Suvà D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC, Baumer K, Kindler V, Stamenkovic I.

Cancer Res. 2008 Apr 1;68(7):2176-85. doi: 10.1158/0008-5472.CAN-07-1761.

39.

Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations.

Suvà ML, Cironi L, Riggi N, Stamenkovic I.

J Pathol. 2007 Oct;213(2):117-30. Review.

PMID:
17703479
40.

Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET.

Riggi N, Cironi L, Suvà ML, Stamenkovic I.

J Pathol. 2007 Sep;213(1):4-20. Review.

PMID:
17691072
41.

Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.

Riggi N, Cironi L, Provero P, Suvà ML, Stehle JC, Baumer K, Guillou L, Stamenkovic I.

Cancer Res. 2006 Jul 15;66(14):7016-23.

42.

Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.

Riggi N, Cironi L, Provero P, Suvà ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I.

Cancer Res. 2005 Dec 15;65(24):11459-68.

43.

Environmental reduplicative paramnesia in a case of atypical Alzheimer's disease.

von Gunten A, Miklossy J, Suvà ML, Hof PR, Glannakopoulos P.

Neurocase. 2005 Jun;11(3):216-26.

PMID:
16006343
44.

Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas.

Lahav R, Suvà ML, Rimoldi D, Patterson PH, Stamenkovic I.

Cancer Res. 2004 Dec 15;64(24):8945-53.

45.

Environmental reduplicative paramnesia in a case of atypical Alzheimer's disease.

von Gunten A, Miklossy J, Suvà ML, Hof PR, Giannakopoulos P.

J Neurol. 2004 Jun;251(6):750-2. No abstract available.

PMID:
15311354

Supplemental Content

Support Center